Delivery Order SPE2DB22D3301-SPE2DB25FY9JD
Award Date 8/13/25
Potential Completion Date 8/14/25
Potential Value $1.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,325.14 for Zepbound 5 mg/0.5 ml pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing one of many...
- The Defense Logistics Agency awarded a delivery order valued at $1,908.64 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on September 4, 2025, with completion scheduled for September 5, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $9,727.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 12, 2025, with completion due by August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $11,438.70 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in diabetes and weight management treatment, reflecting DLA's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,963.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on August 7, 2025, with completion expected by August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order valued at $1,284.26 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on April 21, 2025, with completion expected by April 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used in diabetes and weight management treatment, reflecting the...
- The Defense Logistics Agency awarded a $5,621.91 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with an ultimate completion date of September 17, 2025. This firm fixed price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,574.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on April 24, 2025, with an ultimate completion date of April 25, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $3,386.63 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in diabetes and weight management treatment, representing a specialized pharmaceutical...